Does Rallies show Form 4 insider transactions for MLYS?

Yes. Rallies tracks MLYS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MLYS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MLYS. It does not provide personalized investment advice.

MLYS (Mineralys Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Mineralys Therapeutics, Inc. Common Stock (MLYS) is a publicly traded Healthcare sector company. As of May 20, 2026, MLYS trades at $28.45 with a market cap of $2.18B and a P/E ratio of -12.11. MLYS moved +9.30% today. Year to date, MLYS is -20.27%; over the trailing twelve months it is +76.58%. Its 52-week range spans $8.24 to $47.65. Analyst consensus is strong buy with an average price target of $51.17. Rallies surfaces MLYS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MLYS stock inside the company?

Recent MLYS insider activity includes Rodman David Malcom sold 417, Rodman David Malcom sold 14.06K, Rodman David Malcom sold 6.35K, Rodman David Malcom sold 2.17K, and Rodman David Malcom sold 416. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MLYS Key Metrics

Key financial metrics for MLYS
Metric	Value
Price	$28.45
Market Cap	$2.18B
P/E Ratio	-12.11
EPS	$-2.29
Dividend Yield	0.00%
52-Week High	$47.65
52-Week Low	$8.24
Volume	4.05M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-154.65M
Gross Margin	0.00%

Recent MLYS Insider Trades

Rodman David Malcom sold 417 (~$11.49K) on May 18, 2026.
Rodman David Malcom sold 14.06K (~$401.79K) on May 13, 2026.
Rodman David Malcom sold 6.35K (~$186.35K) on May 12, 2026.
Rodman David Malcom sold 2.17K (~$64.50K) on May 11, 2026.
Rodman David Malcom sold 416 (~$13.03K) on Apr 17, 2026.

Latest MLYS News

Mineralys Announces FDA Acceptance of Lorundrostat NDA, PDUFA Date Set for December 22, 2026 — May 6, 2026
Mineralys Appoints Jeffrey Munsie as CLO with 90k Options, 67.9k RSUs — Mar 24, 2026
Mineralys Reports $656.6M Cash, FDA Accepts Lorundrostat NDA with Dec 22, 2026 PDUFA — Mar 12, 2026

MLYS Analyst Consensus

8 analysts cover MLYS: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $51.17.

Common questions about MLYS

Who is trading MLYS stock inside the company?: Recent MLYS insider activity includes Rodman David Malcom sold 417, Rodman David Malcom sold 14.06K, Rodman David Malcom sold 6.35K, Rodman David Malcom sold 2.17K, and Rodman David Malcom sold 416. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MLYS?: Yes. Rallies tracks MLYS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MLYS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MLYS. It does not provide personalized investment advice.